

*Unless otherwise defined herein, the capitalised terms used in this announcement have the same meaning as those used in the Company's announcements released on 3 July 2024.*

5 July 2024

**Physiomics Plc  
("Physiomics" or the "Company")**

**Result of WRAP Retail Offer**

Physiomics plc, (AIM: PYC), is pleased to announce, further to the announcements on 3 July 2024, the completion of the WRAP Retail Offer, at the same issue price as the previously announced Placing (together, the "Fundraise"). The WRAP Retail Offer, which closed at 4:30 p.m. yesterday and which was oversubscribed, has raised gross proceeds of £25,000 through the issue of a total of 4,166,667 new Ordinary Shares to existing retail shareholders in the United Kingdom.

The Fundraise, which is conditional on Admission, raises gross proceeds of, in aggregate, £406,417, via the issue of 63,569,573 Placing Shares pursuant to the Placing and 4,166,667 WRAP Retail Offer Shares pursuant to the WRAP Retail Offer.

**Use of Proceeds**

In order to further develop its business and accelerate growth, the Company targeted a raise of £406,417 with the intention of using the net proceeds of the fundraise towards activities including:

- Recruitment of a Head of Mathematical Modelling Service Line to accelerate conversion of the pipeline and drive operational excellence.
- Further investment in Business Development and Marketing to build and strengthen the pipeline, expand into new therapeutic areas, develop its data science offering and launch its biostatistics offering.
- Build a biostatistics capability, including team expansion, development of processes, acquisition of necessary tools and exploration of strategic options.
- Implementation of the personalised dosing tool on the DoseMeRx Platform, enabling it to be available to clinicians across the US and deliver on a study in partnership with DoseMeRx to further develop the tools G-CSF functionality.

**Admission and Total Voting Rights**

Applications have been made for the Placing Shares and the WRAP Retail Offer Shares to be admitted to trading on AIM, which is expected to take effect and dealings to commence at 8:00 a.m. on or around 9 July 2024 ("Admission").

Following Admission, the Company will have 203,208,718 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company will be 203,208,718. These figure may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

**For further information, please contact:**

**Physiomics plc**  
Dr Peter Sargent, CEO  
+44 (0)1235 841575

**Hybridan LLP (Broker)**  
Claire Louise Noyce  
+44 (0) 203 764 2341

**Strand Hanson Ltd (NOMAD)**  
James Dance & James Bellman  
+44 (0)20 7409 3494

**Winterflood Retail Access Platform**  
Joe Winkley & Sophia Bechev  
+44 (0)20 8100 0000

Further information on the Company can be found on its website at [www.physiomics.co.uk](http://www.physiomics.co.uk).

The Company's LEI is 213800A71DSZ6ABMTQ91.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROIQKQBKDBKBDOK